Novel neoadjuvant immunochemotherapy followed by surgical resection for intrathyroidal thymic carcinoma: a case report and literature review

Background Intrathyroidal thymic carcinoma (ITC) is an exceptionally rare and aggressive malignancy. Due to its rarity and overlapping features with other thyroid cancers, standardized treatment protocols for advanced, locally invasive ITC are lacking. This report presents a case of locally advanced ITC with tracheoesophageal invasion, successfully treated with a novel multimodal approach centered on neoadjuvant immunochemotherapy. Case presentation A 47-year-old male presented with a right cervical mass exhibiting progressive growth and local invasion on imaging. Core needle biopsy and comprehensive immunohistochemical profiling confirmed the diagnosis of ITC (squamous cell carcinoma), with a PD-L1 CPS of 3. After initial consultation, the patient subsequently received a novel neoadjuvant regimen combining pembrolizumab, albumin-bound paclitaxel, and carboplatin for four cycles. This treatment resulted in significant tumor shrinkage, enabling a subsequent extended radical thyroidectomy. Pathological examination of the resected specimen confirmed a partial pathological response with focal residual disease and limited nodal metastasis. The treatment course was consolidated with postoperative adjuvant radiotherapy. Conclusion This case demonstrates that neoadjuvant immunochemotherapy can be a highly effective and feasible strategy for downsizing locally advanced ITC, thereby converting inoperable tumors into resectable ones. The successful application of this multimodal regimen, culminating in a favorable pathological response and successful surgical resection, provides a valuable paradigm for managing this challenging disease. Our experience suggests that this innovative approach warrants further investigation as a potential new standard of care for selected patients with advanced ITC.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1818294
Primary Topic
Myasthenia Gravis and Thymoma
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Novel neoadjuvant immunochemotherapy followed by surgical resection for intrathyroidal thymic carcinoma: a case report and literature review

张珍华, Zhaoyang Shang, SUN Wencong, Xinhui Wang et al.
4 links
Frontiers in Oncology
Myasthenia Gravis and Thymoma
article

Novel neoadjuvant immunochemotherapy followed by surgical resection for intrathyroidal thymic carcinoma: a case report and literature review

张珍华, Zhaoyang Shang, SUN Wencong, Xinhui Wang, Guoqing Li, Zijie Su, Chuangxin Lu
article en

Abstract

Background Intrathyroidal thymic carcinoma (ITC) is an exceptionally rare and aggressive malignancy. Due to its rarity and overlapping features with other thyroid cancers, standardized treatment protocols for advanced, locally invasive ITC are lacking. This report presents a case of locally advanced ITC with tracheoesophageal invasion, successfully treated with a novel multimodal approach centered on neoadjuvant immunochemotherapy. Case presentation A 47-year-old male presented with a right cervical mass exhibiting progressive growth and local invasion on imaging. Core needle biopsy and comprehensive immunohistochemical profiling confirmed the diagnosis of ITC (squamous cell carcinoma), with a PD-L1 CPS of 3. After initial consultation, the patient subsequently received a novel neoadjuvant regimen combining pembrolizumab, albumin-bound paclitaxel, and carboplatin for four cycles. This treatment resulted in significant tumor shrinkage, enabling a subsequent extended radical thyroidectomy. Pathological examination of the resected specimen confirmed a partial pathological response with focal residual disease and limited nodal metastasis. The treatment course was consolidated with postoperative adjuvant radiotherapy. Conclusion This case demonstrates that neoadjuvant immunochemotherapy can be a highly effective and feasible strategy for downsizing locally advanced ITC, thereby converting inoperable tumors into resectable ones. The successful application of this multimodal regimen, culminating in a favorable pathological response and successful surgical resection, provides a valuable paradigm for managing this challenging disease. Our experience suggests that this innovative approach warrants further investigation as a potential new standard of care for selected patients with advanced ITC.

Frontiers in OncologyVol. 16
Zhengzhou University (CN), Henan Provincial People's Hospital (CN), Zhengzhou People's Hospital (CN)
Good health and well-being
Myasthenia Gravis and Thymoma
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon